Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (121-130 of 181) with videos related to

Pageof 19
Sort By:
Journal of the International AIDS Society|November 15, 2014
Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patientsDaniel Podzamczer, Jhon Fredy Rojas, Isabel Neves, et al.
Antiviral Therapy|June 26, 2014
Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravirJosé L Blanco, Ana Gonzalez-Cordón, Josep M Llibre, et al.
Open Forum Infectious Diseases|January 28, 2025
Using Anal Cytology and Human Papillomavirus DNA and E6/E7 mRNA Detection to Optimize High-Resolution Anoscopy Referrals in Men Who Have Sex With Men With HIVAna C Silva-Klug, Sònia Paytubi, Montserrat Torres, et al.
The Journal of Antimicrobial Chemotherapy|April 12, 2022
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 studyMaria Saumoy, Jose Luís Sánchez-Quesada, Lambert Assoumou, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 6, 2006
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohortJuan Berenguer, María Jesús Pérez-Elías, José María Bellón, et al.
Lancet (London, England)|September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialJoel Gallant, Adriano Lazzarin, Anthony Mills, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|October 22, 2011
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]Antonio Javier Blasco, José Ramón Arribas, Bonaventura Clotet, et al.
Antiviral Therapy|May 12, 2009
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppressionFederico Pulido, Ignacio Pérez-Valero, Rafael Delgado, et al.
Nature Communications|March 4, 2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
The Lancet. HIV|August 6, 2021
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trialJhon Rojas, Elisa de Lazzari, Eugenia Negredo, et al.
Pageof 19

Showing results (121-130 of 181) with videos related to

Sort By:
Pageof 19
Journal of the International AIDS Society|November 15, 2014
Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patientsDaniel Podzamczer, Jhon Fredy Rojas, Isabel Neves, et al.
Antiviral Therapy|June 26, 2014
Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravirJosé L Blanco, Ana Gonzalez-Cordón, Josep M Llibre, et al.
Open Forum Infectious Diseases|January 28, 2025
Using Anal Cytology and Human Papillomavirus DNA and E6/E7 mRNA Detection to Optimize High-Resolution Anoscopy Referrals in Men Who Have Sex With Men With HIVAna C Silva-Klug, Sònia Paytubi, Montserrat Torres, et al.
The Journal of Antimicrobial Chemotherapy|April 12, 2022
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 studyMaria Saumoy, Jose Luís Sánchez-Quesada, Lambert Assoumou, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 6, 2006
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohortJuan Berenguer, María Jesús Pérez-Elías, José María Bellón, et al.
Lancet (London, England)|September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialJoel Gallant, Adriano Lazzarin, Anthony Mills, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|October 22, 2011
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]Antonio Javier Blasco, José Ramón Arribas, Bonaventura Clotet, et al.
Antiviral Therapy|May 12, 2009
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppressionFederico Pulido, Ignacio Pérez-Valero, Rafael Delgado, et al.
Nature Communications|March 4, 2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trialFrancesc Català-Moll, Carlos Blázquez-Bondia, Judit Farré-Badia, et al.
The Lancet. HIV|August 6, 2021
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trialJhon Rojas, Elisa de Lazzari, Eugenia Negredo, et al.
Pageof 19